KDM6 and KDM4 histone lysine demethylases emerge as molecular therapeutic targets in human acute myeloid leukemia

Dysregulated function in chromatin modifying enzymes remains an important hallmark in acute myeloid leukemia (AML) pathogenesis (1). Growing bodies of evidences highlight involvement of histone demethylases in tumorigenesis (2, 3). Kdm1a, an H3K4Me2/1 and H3K9Me2/1 demethylase was demonstrated to sustain oncogenic potential of MLL-AF9-expressing leukemia stem cells (LSCs) (4). Kdm5b, another H3K4Me3/2 demethylase has been suggested as a tumor suppressor in MLL-rearranged leukemia, inversely affecting LSC function (5).

Source: Experimental Hematology - October 27, 2017 Category: Hematology Authors: Liberalis Debraj Boila, Shankha Subhra Chatterjee, Debasis Banerjee, Amitava Sengupta Tags: Brief Communications Source Type: research